Table 4 Breast cancer risk as a function of number of SLE autoantibodies, compared to the general population
From: Association of systemic lupus erythematosus autoantibody diversity with breast cancer protection
Number of autoantibodies | N | No. obs. | No. exp. | SLE cohort SIR (95%CI) | p value | AA* SIR (95%CI) | AA p value | Non-AA^ SIR (95%CI) | Non-AA p value |
|---|---|---|---|---|---|---|---|---|---|
0–2 antibodies | 1301 | 15 | 17.8 | 0.84 (0.47–1.39) | 0.60 | 1.72 (0.86–3.08) | 0.12 | 0.35 (0.10–0.90) | 0.023 |
3+ antibodies | 1130 | 7 | 17.1 | 0.41 (0.16–0.84) | 0.010 | 0.65 (0.21–1.51) | 0.43 | 0.21 (0.03–0.77) | 0.010 |